MK-6240

Phase 3Small molecule

Roche

MK-6240 is one of 76 small molecule programs targeting Down syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Down SyndromeActive, not recruiting

CognitionActive, not recruiting

Down SyndromePhase 3

Active, not recruiting

CognitionPhase 1

Active, not recruiting

Competition

Competitive Landscape

191 competitors in Cognition

#DrugCompanyPhaseTrials

MK-6240

Roche

Phase 3

1 2

Activella

Eli Lilly

Preclinical

2 3

Estrace

Novo Nordisk

Preclinical

2 4

Ozempic

Novo Nordisk

Preclinical

1 5

Resotran

Takeda

Preclinical

1 6

Veramyst

GSK

Preclinical

1 7

Galvus

Novartis

Preclinical

1 8

Marinol

Alnylam Pharmaceuticals

Preclinical

1 9

Depo-Provera

Pfizer

Preclinical

1 10

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Alzheimer's Disease

NCT06600880

Clinical

Trials by Indication[1]

Alzheimer's Disease2 trials

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

Not yet recruiting·—·Phase 1·NCT06600880·6 enrolled

Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease

Completed·JJose Gutierrez, MD, MPH··NCT04510168·238 enrolled

Imaging1 trial

Study of Tau Imaging With the Use of [18F]MK-6240 Tracer

Enrolling by invitation·TTammie L. S. Benzinger, MD, PhD··NCT04104659·200 enrolled

Down syndrome1 trial

LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

Terminated·LLuMind IDSC Foundation·Phase 3·NCT06860373·5 enrolled

Cognition1 trial

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Completed· Roche logo

Roche·Phase 1·NCT04566003·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MK-6240. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK-6240 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK-6240. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

MK-6240

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Alzheimer's Disease2 trials

Imaging1 trial

Down syndrome1 trial

Cognition1 trial

References

Drug Info

Quick Facts

Related News